Local High-Dose Radiotherapy and Sparing of Normal Tissue Using Intensity-Modulated Radiotherapy (IMRT) for Mucosal Melanoma of the Nasal Cavity and Paranasal Sinuses

2007 ◽  
Vol 183 (2) ◽  
pp. 63-68 ◽  
Author(s):  
Stephanie E. Combs ◽  
Stephan Konkel ◽  
Christoph Thilmann ◽  
Jürgen Debus ◽  
Daniela Schulz-Ertner
Keyword(s):  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Normal Tissue ◽  
Intensity Modulated Radiotherapy ◽  
Mucosal Melanoma ◽  
High Dose ◽  
Intensity Modulated

Post-operative intensity-modulated radiotherapy for malignancies of the nasal cavity and paranasal sinuses

2007 ◽  
Vol 85 (3) ◽  
pp. 385-391 ◽  
Author(s):  
Piet Dirix ◽  
Sandra Nuyts ◽  
Bianca Vanstraelen ◽  
An Nulens ◽  
Robert Hermans ◽  
...  
Keyword(s):  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated

Concurrent high-dose intensity-modulated radiotherapy and chemotherapy for unresectable locally advanced and metastatic pancreatic cancer: a pilot study

2021 ◽  
pp. 1-6
Author(s):  
Kenichi Matsumoto ◽  
Akihiko Miyamoto ◽  
Tomoya Kawase ◽  
Taro Murai ◽  
Yuta Shibamoto
Keyword(s):  
Pancreatic Cancer ◽  
Locally Advanced ◽  
Intensity Modulated Radiotherapy ◽  
Dose Intensity ◽  
Progression Free Survival ◽  
Concurrent Chemotherapy ◽  
Metastatic Pancreatic Cancer ◽  
High Dose ◽  
Chemotherapy Group ◽  
Intensity Modulated

Abstract Aim: To evaluate the efficacy of concurrent chemotherapy and high-dose (≥55 Gy) intensity-modulated radiotherapy (CCIMRT) in comparison with chemotherapy alone and intensity-modulated radiotherapy (IMRT) alone for unresectable locally advanced or metastatic pancreatic cancer. Methods: Forty-six patients with pancreatic cancer undergoing CCIMRT (n = 17), chemotherapy alone (n = 16) or IMRT alone (n = 13) were analysed. Overall survival (OS), locoregional progression-free survival (LRPFS) and gastrointestinal toxicities were evaluated. The median radiation dose was 60 Gy (range, 55–60) delivered in a median of 25 fractions (range, 24–30). Gemcitabine (GEM) alone, GEM + S-1, S-1 alone, FOLFIRINOX and GEM + nab-paclitaxel were used in CCIMRT and chemo-monotherapy. Results: The 1-year OS rate was 69% in the CCIMRT group, 27% in the chemotherapy group and 38% in the IMRT group (p = 0·12). The 1-year LRPFS rate was 73, 0 and 40% in the 3 groups, respectively (p = 0·012). Acute Grade ≥ 2 gastrointestinal toxicity (nausea, diarrhea) was observed in 12% (2/17) in the CCIMRT group, 25% (4/16) in the chemotherapy group and 7·7% (1/13) in the IMRT group (p = 0·38). Late Grade 3 gastrointestinal bleeding was observed in 6·3% (1/16) in the chemotherapy group. Conclusion: High-dose CCIMRT yielded acceptable toxicity and favorable OS and LRPFS.

Sign in / Sign up

Export Citation Format

Share Document